Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger

doi:10.7150/thno.11251

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

Hans Jürgen Wester
, Ulrich Keller
, Margret Schottelius
, Ambros Beer
, Kathrin Philipp-Abbrederis
, Frauke Hoffmann
, Jakub Šimeček
, Carlos Gerngross
, Michael Lassmann
, Ken Herrmann
, Natalia Pellegata
, Martina Rudelius
, Horst Kessler
, Markus Schwaiger

Technical University of Munich
University of Ulm
Scintomics GmbH
University Hospital Würzburg
Helmholtz Zentrum München German Research Center for Environmental Health
University of Würzburg
Kind AbdulAziz University

Research output: Contribution to journal › Article › peer-review

185 Scopus citations

Abstract

Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [⁶⁸Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [⁶⁸Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [⁶⁸Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [⁶⁸Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.

Original language	English
Pages (from-to)	618-630
Number of pages	13
Journal	Theranostics
Volume	5
Issue number	6
DOIs	https://doi.org/10.7150/thno.11251
State	Published - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CXCR4
Chemokine receptor
Lymphoma, in vivo imaging
Positron emission tomography

Access to Document

10.7150/thno.11251

Cite this

Wester, H. J., Keller, U., Schottelius, M., Beer, A., Philipp-Abbrederis, K., Hoffmann, F., Šimeček, J., Gerngross, C., Lassmann, M., Herrmann, K., Pellegata, N., Rudelius, M., Kessler, H., & Schwaiger, M. (2015). Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics, 5(6), 618-630. https://doi.org/10.7150/thno.11251

@article{1cd35ea1f2384501831a5f29e9ea756f,

title = "Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging",

abstract = "Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [68Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [68Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [68Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [68Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.",

keywords = "CXCR4, Chemokine receptor, Lymphoma, in vivo imaging, Positron emission tomography",

author = "Wester, \{Hans J{\"u}rgen\} and Ulrich Keller and Margret Schottelius and Ambros Beer and Kathrin Philipp-Abbrederis and Frauke Hoffmann and Jakub {\v S}ime{\v c}ek and Carlos Gerngross and Michael Lassmann and Ken Herrmann and Natalia Pellegata and Martina Rudelius and Horst Kessler and Markus Schwaiger",

note = "Publisher Copyright: {\textcopyright} 2015 Ivyspring International Publisher.",

year = "2015",

doi = "10.7150/thno.11251",

language = "English",

volume = "5",

pages = "618--630",

journal = "Theranostics",

issn = "1838-7640",

publisher = "Ivyspring International Publisher",

number = "6",

}

Wester, HJ, Keller, U, Schottelius, M, Beer, A, Philipp-Abbrederis, K, Hoffmann, F, Šimeček, J, Gerngross, C, Lassmann, M, Herrmann, K, Pellegata, N, Rudelius, M, Kessler, H & Schwaiger, M 2015, 'Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging', Theranostics, vol. 5, no. 6, pp. 618-630. https://doi.org/10.7150/thno.11251

TY - JOUR

T1 - Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

AU - Wester, Hans Jürgen

AU - Keller, Ulrich

AU - Schottelius, Margret

AU - Beer, Ambros

AU - Philipp-Abbrederis, Kathrin

AU - Hoffmann, Frauke

AU - Šimeček, Jakub

AU - Gerngross, Carlos

AU - Lassmann, Michael

AU - Herrmann, Ken

AU - Pellegata, Natalia

AU - Rudelius, Martina

AU - Kessler, Horst

AU - Schwaiger, Markus

PY - 2015

Y1 - 2015

N2 - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [68Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [68Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [68Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [68Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.

AB - Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [68Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [68Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [68Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [68Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.

KW - CXCR4

KW - Chemokine receptor

KW - Lymphoma, in vivo imaging

KW - Positron emission tomography

UR - https://www.scopus.com/pages/publications/84926192140

U2 - 10.7150/thno.11251

DO - 10.7150/thno.11251

M3 - Article

C2 - 25825601

AN - SCOPUS:84926192140

SN - 1838-7640

VL - 5

SP - 618

EP - 630

JO - Theranostics

JF - Theranostics

IS - 6

ER -

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this